Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30
Published January 10, 2018 · Recall initiated: October 20, 2017
Summary
FDA records drug Class II recall D-0151-2018, published January 10, 2018 and initiated October 20, 2017. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 1972 bottles; Lot: Lot: S84026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Pfizer Inc.
- Distributor
- Nationwide in the USA
- Lot
- Lot: S84026
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units per 4 mL, 4ml-vial, Rx Only,August 6, 2025
- FDABicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only,August 6, 2025
- FDADOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials,July 2, 2025
- FDALabetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL), 4 mL Single-dose Carpuject, Sterile CartridgeJuly 3, 2024
- FDAdiphenoxylate hydrochloride and atropine sulfate tablets, USP, 2.5 mg/0.025 mg, a) 100-count bottle (NDCJanuary 10, 2018
- FDARapunzel Vegetable Bouillon ( no added salt ), 2.4 oz. net weight, in a thick paper sleeve containing 8January 10, 2018
Questions about this recall
Was Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30 recalled?
Yes. FDA published recall D-0151-2018 on January 10, 2018. Reported hazard: SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
What should I do if I have this product?
Voluntary: Firm initiated · Letter